Cambridge Bioscience is pleased to announce a new partnership with Absea, a global leader in proteomics and interactomics solutions, to expand access to tools for protein science research across the UK and Ireland.
Absea’s extensive product range includes over 13,000 soluble proteins, representing 65% of the human proteome, and more than 7,000 meticulously validated monoclonal antibodies. These resources play a crucial role in advancing AI-driven protein design, diagnostics, and drug development.
With key facilities in Berlin, China, and the San Francisco Bay Area, Absea supports scientists worldwide in pushing the boundaries of therapeutic and proteomic innovation. This collaboration will make their solutions more accessible to researchers aiming to solve complex scientific challenges.
Cambridge Bioscience is excited to connect UK and Irish scientists with these innovative tools, driving forward discoveries in diagnostics and therapeutic development.